Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT02847559 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic (Malignant) Meningioma
Atypical Meningioma
Grade II Meningioma
Grade III Meningioma
Recurrent Meningioma
Supratentorial Meningioma

Interventions

BIOLOGICAL: Bevacizumab
PROCEDURE: Electric Field Therapy
DEVICE: NovoTTF-200A Device
PROCEDURE: Quality-of-Life Assessment

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]